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Abstract 
Objectives: Trisodium citrate represents an interesting alternative to heparin for the prevention of circuit clotting 
during extracorporeal procedures, but some protocols require not commercially available citrate concentrations. 
There is very little information available in the literature about the stability of diluted citrate solutions. This study 
is aimed to evaluate the long-term stability, efficacy and toxicity of 35 mM and 90 mM trisodium citrate solutions 
prepared by diluting commercially available sterile solution, stored in plastic syringes, and used as anticoagulant 
during the citrate bag changes in coupled plasma filtration adsorption (CPFA) technique in the COMPACT-2 
clinical trial. 
Methods: The chemical stability of trisodium citrate solutions was evaluated by HPLC after 7, 14, 21 and 28 days 
of storage. The sterility tests were performed both immediately after preparation and after 28 days of storage. 
Results: After 28 days of storage, the concentration of trisodium citrate do not change in comparison to day 1, and 
both the solutions passed the sterility test. A preliminary test indicated that 35 mM solution is not enough to 
ensure an effective anticoagulant action on extracorporeal circuit, but the 90 mM solution was successfully used 
during a total of 7 CPFA treatments in 2 patients without clinical signs of toxicity.  
Conclusions: Both the 35 mM and 90 mM solutions are chemically and microbiologically stable for 28 days when 
stored at room temperature in 50 mL syringes protected by light. The 90 mM solution is effective and safe as 
regional anticoagulant in the CPFA protocol.    
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INTRODUCTION 
 
The hemodialysis procedure requires the maintenance of an adequate blood flow into the extracorporeal circuit, 
so the use of an anticoagulant is essential to avoid the intraluminal thrombus formation that could decrease the 
hemofiltration efficiency. Heparin is a systemic anticoagulant commonly used as thrombolytic agent in different 
pathological conditions and in the prevention of thrombus formation during a number of extracorporeal medical 
procedures.1 Heparin exerts its anticoagulant activity through inhibition of factor Xa and thrombine II, leading to 
the block of coagulation cascade before the activation of fibrine from fibrinogen.1 One of the most important 
drawbacks in the use of heparin as anticoagulant during hemodialysis, is its long-lasting action. The biological 
half-life of heparin, in fact, is in the range of hours, and this feature exposes the patients to potential systemic 
anticoagulant action, with increased risk of thrombocytopenia, bleeding and haemorrhage.2 This risk is 
particularly relevant in uremic, septic or critically ill patients, as they have an increased likelihood of bleeding due 
to recent surgery, trauma, mucosal lesions or coagulopathy.3-5 Moreover, binding of endothelial antithrombin to 
administrated heparin inhibits its anti-inflammatory actions and prevents local prostacyclin formation that, in turn, 
may even aggravate sepsis-mediated disorders.3 6 
Trisodium citrate represent an interesting alternative to heparin when anticoagulant action is required only locally 
(e.g. central venous catheter or extracorporeal circuit during hemofiltration or hemodialysis).3-5 7 The regional 
anticoagulant action of trisodium citrate is due to its ability to chelate the free ionized calcium in the blood, with 
the consequence of the blockage of calcium-dependent clotting formation in the coagulation cascade. By 
chelating calcium, citrate acts regionally as an anticoagulant when administered pre-filter, and thereby reduces the 
risk of bleeding compared to systemic anticoagulation.4 During continuous renal replacement therapy (CRRT), an 
optimal regional anticoagulant activity occurs when the ionized calcium concentration in the extracorporeal 
circuit is below 0.35 mmol⁄L.8 The remaining citrate, free and calcium bound, is partially removed by 
hemofiltration (from 20% to 80%, depending on the blood and effluent flow rate, and CRRT modality), and 
partially enters the systemic circulation. When citrate reach the bloodstream, its anticoagulant action is rapidly 
reverted because the calcium citrate chelates are efficiently metabolized by liver and muscles, and free calcium 
ions become again available in the blood.3 9 10 Furthermore, the normal patient’s systemic calcium level is 
commonly restored by post-hemofilter replacement infusion of calcium solution.11 
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Recent reviews on clinical studies comparing the regional citrate anticoagulation versus systemic heparinisation 
in critically ill patients treated with CRRT, indicate that citrate is superior in terms of safety, efficacy and costs, 
and allows better filter survival times with higher delivered CRRT doses.3-5 7 8 10 11 Consequently, the most recent 
Clinical Practice Guidelines for Acute Kidney Injury recommend the use of citrate as anticoagulant in patients 
requiring CRRT.12 
Different methods of regional citrate anticoagulation have been described in the literature: in some protocols, 
citrate is administered in the extracorporeal circuit as a separate solution, whereas, in other protocols, citrate is 
added to a calcium-free predilution replacement fluid.7 8 10 11 13 14  
The administration of citrate may cause serious adverse effects, such as metabolic alkalosis and acidosis, hyper- 
and hyponatremia, and hypocalcemia. Thus, it is important to carefully design citrate anticoagulation protocols, 
and it is preferred to incorporate an appropriate citrate module in the CRRT device, in order to continuously 
monitor the citrate concentration in the prefilter. Finally, the patient’s level of electrolytes and calcium, and the 
acid–base status should be frequently monitored, in order to minimize the risk of toxicity.15 16  
Septic shock is a systemic imbalance of proinflammatory and anti-inflammatory response that can be induced by 
the endotoxin of Gram-negative bacteria. Therefore, the treatment strategies should pursue a twofold objective: to 
counteract the infection and to rebalance the immune response. While the first objective is achieved by the 
administration of antibiotics, the second could be accomplished by various blood purification techniques, among 
which the coupled plasma filtration adsorption (CPFA), that is able to unselectively remove the majority of 
soluble inflammatory mediators involved in sepsis pathogenesis.17 18 The efficacy of CPFA in the treatment of 
critically ill patients with septic shock has been compared with standard care in the COMPACT multicentre 
randomised controlled clinical trial (NCT00332371), but the trial was prematurely terminated on the grounds of 
the high number of protocol violations in the CPFA arm in terms of low volume of plasma treated per day.19 The 
main reason for not reaching the prescribed volume of plasma treated, was the clotting of the circuit, in spite of 
the use of heparin for anticoagulation. In an attempt to overcome this problem, the extracorporeal circuit has been 
modified, in order to support regional anticoagulation with citrate, and a new multicentre randomised controlled 
clinical trial, COMPACT-2 (NCT01639664) has been started. 
The aim of this study is to evaluate the long-term stability, efficacy and toxicity of two different concentrations of 
trisodium citrate (35 and 90 mM) stored in plastic syringes, suitable for the use in CPFA procedure. There is very 
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little information available in the literature about the chemical stability of diluted citrate solutions, and published 
papers reported only the data on the 136 mM solution.20 21 In addition, no information about the sterility 
maintenance of these kinds of solution during storage are reported. 
The solutions were prepared by diluting commercially available sterile trisodium citrate concentrate with sterile 
0.9% sodium chloride solution under sterile conditions, and were stored in 50 mL syringes for up to 28 days at 
room temperature. The solutions were then used as regional anticoagulant during CPFA therapy in the 
COMPACT-2 clinical trial. The immediate availability of citrate syringes ready-to-use for Nephrology and 
Intensive Care Unit (ICU) is very important in the treatment of patients with acute kidney failure or septic shock, 
as the prompt start of CRRT or CPFA procedures is critical for the chances of a successful treatment.22 23 
 
 
METHODS 
 
Chemicals, reagents and materials 
Commercially available trisodium citrate sterile concentrate solution (46.7%) was purchased from Monico 
(Mestre/Venice, Italy), sterile 0.9% sodium chloride  solution was provided by Baxter (Rome, Italy), sterile 50 
mL polypropylene (PP) syringes UV-protected with luer lock caps were purchased from Artsana (Como, Italy). 
Monobasic potassium phosphate, phosphoric acid, standard trisodium citrate, sodium hydroxide, hydrochloric 
acid, 30% hydrogen peroxide, and methanol HPLC-grade were provided by Sigma-Aldrich (Milan, Italy).  
 
Preparation of trisodium citrate solutions 
Two different concentrations of trisodium citrate were prepared: 35 mM (1.029%) and 90 mM (2.65%). 
Trisodium citrate solutions were prepared by diluting commercially available sterile concentrate (1.59 M, 46.7%) 
with sterile 0.9% sodium chloride solution under sterile conditions, in accordance with the European 
Pharmacopoeia24. The procedure was identical to that usually employed in our hospital pharmacy for the 
preparation of similar solutions for parenteral administration. This standard procedure has been validated and is 
regularly monitored. In order to assure aseptic filling of the syringes, the whole procedure were performed in a 
glove box isolator (Isoclean® Healthcare Platform Isolator HPI-G3, manifactured by Esco Pharma, 
6 
 
Rotherham, UK), avoiding the direct exposition of solutions and syringes to the room environment or to 
compounding personnel. The filled syringes were then capped with a sterile luer lock tip, delivered to 
Nephrology unit and ICU, and stored at room temperature (21 ± 2 °C) protected from direct light.  
 
HPLC analysis 
Trisodium citrate concentration was determined by isocratic reverse-phase HPLC by a method adapted from the 
official method 986.13 of the Association of Official Analytical Chemists.25 HPLC system consisted of a YL9300 
HPLC (Young Lin Instruments, Anyang, Korea) equipped with a vacuum degasser, a quaternary pump, a manual 
injector with a 200 μL loop, and an UV-Vis detector set at 200 and 215 nm. The analytical column was a 
Symmetry C18 (250 × 4.6 mm i.d., particle size 5 μm), equipped with a Symmetry C18 guard column, supplied 
by Waters (Vimodrone, Milan, Italy). The mobile phase consisted of a mixture of 0.08 M potassium dihydrogen 
phosphate buffer (adjusted to pH 2.6 with phosphoric acid) and methanol (98:2 v/v), and was delivered at 
1 mL/min at room temperature (21 ± 2°C). Peak heights and areas were recorded on PC and processed with YL-
Clarity software (Young Lin Instruments, Anyang, Korea). In these conditions, the retention time of trisodium 
citrate was about 8 min. Standard curve was calculated by least-squares linear regression from six trisodium 
citrate standard concentrations ranging from 10 to 500 µg/mL (10, 20, 50, 100, 250, and 500 μg/mL), with each 
point consisting of six independent measurements. The concentrations of  20, 100 and 250 μg/mL were used to 
determine accuracy and precision. Accuracy was reported by calculating the bias expressed as (measured 
concentration−nominal concentration)/(nominal concentration))×100, and precision by the coefficient of variation 
(CV) expressed as (S.D./mean)×100. 
Trisodium citrate concentrations of solution stored in the syringes were determined from the peak area ratios 
versus the standard curve.  
 
Forced degradation of trisodium citrate 
In order to verify the specificity of HPLC method of analysis, the degradation of citrate was forced by exposing 
citrate solution to acidic, alkaline or oxidizing condition. For the acidic or alkaline degradation, concentrated 
hydrochloric acid or 6N sodium hydroxide was added to 50 mL aliquots of 35 mM or 90 mM citrate solution in a 
100 mL flask, in order to adjust the pH to about 1 or 12 respectively. For the oxidizing condition, 25 mL of 30% 
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hydrogen peroxide was added to 50 mL of 35 mM or 90 mM citrate solution in a 100 mL flask. The samples were 
incubated at 50°C for 24 hours, and then each flask was made up to volume with deionised water. Three aliquots 
(0.5 mL) of each flask were centrifuged at 15000g for 5 minutes in order to precipitate any insoluble material 
eventually formed. Samples were then analysed by HPLC after a 1:25 v/v (for 35 mM) or 1:50 v/v (for 90 mM) 
dilution in deionised water, and the chromatograms were compared to that of fresh trisodium citrate solution at 
the same concentration. 
 
Stability study 
Syringes containing trisodium citrate solutions were stored at room temperature and kept away from direct 
exposure to light. For each concentration, three syringes were randomly taken for the determination of trisodium 
citrate amount on days 1, 7, 14, and 28. Samples from selected syringes were diluted with deionised water (1:50 
v/v for 35 mM solution, or 1:100 v/v for 90 mM solution), and analysed in triplicate by HPLC.  
Three syringes containing 35 or 90 mM trisodium citrate solutions were stored at 4°C, and the trisodium citrate 
amount was evaluated after 28 days of storage. 
 
Sterility test 
The sterility of the solutions was tested by the Chemical Laboratory of CCIA (Turin Chamber of Commerce) 
according to the European Pharmacopoeia essays.24 The laboratory is certified ISO 9001, and accredited in 
accordance with the recognized International Standard of ISO/IEC 17025. 
For each concentration, the sterility tests were done on 4 syringes, from a batch of 40, both immediately after the 
preparation, and after 28 days of storage at room temperature. 
 
Use of trisodium citrate solutions as anticoagulant agent in the CRRT procedure 
The trisodium citrate solutions were used as regional anticoagulant during CPFA therapy in the COMPACT-2 
clinical trial (NCT01639664). CPFA was performed with the use of a four-pump modular treatment (AMPLYA, 
Bellco, Mirandola, Italy) consisting of a plasma filter (0.45 m2 polyethersulfone) and a following absorption on an 
unselective hydrophobic resin cartridge (140 mL for 70 g, with a surface of about 700 m2/g) and a final passage of 
the reconstituted blood through a high-permeability 1.4 m2 polyethersulfone hemofilter, in which convective 
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exchanges may be applied in a postdilution mode. The 10/2 citrate solution is administered through a fifth pump 
in predilution 25%. During the citrate bag changes, the fifth pump is stopped for 3-7 minutes, in order to avoid air 
entrance into the CPFA circuit, but this procedure increases the risk of circuit clotting. For this reason, the circuit 
has been modified by adding an alternative citrate inlet through which a citrate solution, stored in a 50 mL 
external syringe, is pumped at 300 mL/h, so ensuring the right citrate concentration in the CPFA circuit. 
According to the available clinical evidence, CPFA was to be repeated daily, lasting at least 10 h each time, so 
that an average of 0.15 L/kg predicted body weight (PBW) of plasma should have been treated per day.19 
 
 
RESULTS 
 
Validation of HPLC assay 
The method was found to be linear over the range of 10 to 500 μg/mL, with an r2≥0.999 and a mean absolute 
percentage deviation of standards from their nominal concentration <4%. Intra-day accuracy ranged from −1.06 
to 3.11% and inter-day accuracy ranged from −1.45 to 4.05%. Intra-day precision was <4%, while inter-day 
precision was <5%. The limit of quantification (LOQ) of the method was 10 µg/mL. 
 
Forced degradation of trisodium citrate solutions 
The results of forced degradation of trisodium citrate solutions showed that the incubation in oxidizing conditions 
for 24 h cause the formation of almost two new peaks, with a retention time of about 4.5 and 6.2 minutes, with 
only 89.7% of citrate remaining unchanged (Figure 1). The solutions exposed to acidic or alkaline condition for 
24 h showed no sign of degradation, with a mean amount of 98.8% and 99.2% of unmodified trisodium citrate 
respectively. There was no difference in trisodium citrate degradation between 35 or 90 mM concentrations. 
 
Stability study 
During a storage period of 28 days at room temperature in 50 mL PP syringes, the trisodium citrate solutions 
remained clear, colourless, and without the formation of any precipitate. The concentrations of citrate, determined 
by HPLC after 7, 14, 21 and 28 days of storage, do not change in comparison to that of day 1, resulting in the 
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range of 100 ± 10% of the initial concentration (Table 1). Similar results were obtained from syringes stored for 
28 days at 4° C, with a mean percentage of day 1 concentration residual of 99.6 for 35 mM and 102.4 for 90 mM 
solutions.  
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Table 1. Stability of 35 mM and 90 mM trisodium citrate solutions stored at room temperature. Data are the mean 
of three different samples, each analysed in triplicate. 
 
  
Trisodium citrate solution 
 
Days of storage 
1 7 14 21 28 
 
35 mM 
% of day 1 concentration 
residual 
100.0 103.7 ± 3.2 99.7 ± 2.2 106.3 ± 1.9 105.7 ± 2.1 
 
90 mM 
% of day 1 concentration 
residual 
100.0 96.9 ± 3.5 95.4 ± 2.2 98.6 ± 2.6 95.9 ± 2.7 
 
Mean ± standard deviation 
 
 
 
Sterility test 
Both trisodium citrate solutions (35 mM and 90 mM), passed the sterility test both immediately after the 
preparation and after the storage period of 28 days at room temperature in 50 mL PP syringes. 
 
Efficacy of trisodium citrate solutions as anticoagulant in the CRRT procedure 
The use of the external syringe prepared with 35 mM citrate solution was abandoned early because a preliminary 
test indicated that this concentration is not enough to ensure an effective anticoagulant action during the change of 
the citrate-bags. Conversely, the external syringe containing 90 mM citrate solution was used during seven 
complete CPFA treatments in two patients admitted in ICU with septic-shock diagnosis (Table 2). Three sessions 
of CPFA was administered to patient number 1 and four sessions was administered to patient number 2. Both 
patients were treated with a mean of over 0.22L/kg PBW per session. In both patients it was possible to overcome 
10 hours of CPFA treatment without clotting (Table 2). Moreover, after the CPFA session CRRT continued 
without the need of circuit substitution before its normal duration. 
Both patients do not develop clinical signs of citrate toxicity during CPFA/CRRT treatments. 
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Table 2. Clinical characteristics of patients at ICU admission and characteristics of CPFA sessions. 
 
Characteristics Patient 1 Patient 2 
Clinical characteristics of patients   
Sex male female 
Age (years) 64 71 
Predicted body weight (Kg) 63 46 
SAPS 2 54 68 
Systolic blood pressure (mmHg)  95 105 
Lactate (mmol/L) 5.8 3 
Cardiac frequency (bpm) 113 118 
Systemic vascular resistance index (dines s/cm5) 110 1400 
Cardiac index (L/min/m2) 4 2.8 
Temperature (°C) 35.8 36.3 
Central saturation O2 (%) 71 66 
Platelet (x1000/mL) 237000 186000 
White blood cells (x1000/L) 13500 18000 
Bilirubin (mg/dL) 1.1 0.5 
Creatinine (mg/dL) 1 1.3 
Procalcitonin (ng/mL) 59 44 
pH 7.43 7.29 
PT INR 1.4 2.5 
Haematocrit (%) 37 31 
Noradrenaline dosage (µg/Kg/min) 0.2 0.3 
Characteristics of CPFA sessions   
Mean treated plasma (L) 14 11 
Target plasma treated (L) 13 9 
Mean treated plasma/kg PBW (L/Kg) 0.22 0.24 
CPFA Sessions number 3 4 
Mean session duration (h) 12 12 
ICU: Intensive Care Unit; CPFA: Coupled Plasma Filtration Adsorption; SAPS: Simplified Acute Physiology Score; PT: 
Prothrombin Time; INR: International Normalized Ratio; PBW: Predicted Body Weight 
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DISCUSSION 
 
The administration of trisodium citrate solution in the extracorporeal circuit proved to be an effective means of 
regional anticoagulation in patients treated with CPFA, but the commercially available solutions are not suited for 
this application. The aim of this study was to evaluate the chemical and microbiological stability of two different 
concentrations of trisodium citrate solutions, 35 mM and 90 mM, prepared in a hospital pharmacy and stored at 
room temperature in 50 mL syringes “ready-to-use” in ICU. 
The chemical stability was evaluated by HPLC, and the specificity of the method was proved by the separation of 
degradation products from unmodified trisodium citrate in the analysis of sample treated by oxidizing conditions. 
Both the 35 mM and 90 mM trisodium citrate solutions are chemically stable for 28 days when stored at room 
temperature in 50 mL syringes protected by light, as demonstrated by the high percentage of citrate still present 
(at least 95%) in comparison to day 1. 
Results of sterility test demonstrated the microbiological stability of solutions during the storage. 
A preliminary test indicated that 35 mM trisodium citrate concentration is not enough to ensure an effective 
anticoagulant action in the extracorporeal circuit during the change of the citrate bag, for this reason only the 90 
mM concentration was used for CPFA/CRRT treatment. The efficacy of 90 mM trisodium citrate solution as 
regional anticoagulant was demonstrated by the absence of circuit clotting, premature hemofilter change or loss in 
plasma treated in a total of seven sessions administered to two different patients. Moreover, no signs of citrate 
toxicity were observed during treatments, so demonstrating the safety of this anticoagulation procedure.    
In conclusion, our results demonstrate that both the 35 mM and 90 mM trisodium citrate solutions are chemically 
and microbiologically stable for 28 days when stored at room temperature in 50 mL PP syringes protected by 
light. The 90 mM solution prove to be effective and safe as regional anticoagulant during the citrate-bags changes 
in the CPFA protocol, and will be used for the treatment of all patients enrolled in the COMPACT-2 clinical trial. 
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Key messages 
 
What is already known on this subject 
 Recent reviews on clinical studies in critically ill patients treated with CRRT, indicate that regional citrate 
anticoagulation is superior to systemic heparinisation in terms of safety, efficacy and costs, and allows 
better filter survival times with higher delivered CRRT doses. 
 The clinical trial COMPACT, aimed to compare the efficacy of coupled plasma filtration adsorption 
(CPFA) with standard care in the treatment of critically ill patients with septic shock, was prematurely 
terminated because of the high number of protocol violations, mainly due to the clotting of the circuit in 
spite of the use of heparin for anticoagulation. For this reason, the extracorporeal circuit has been 
modified in order to support regional anticoagulation with citrate, and a new clinical trial (COMPACT-2) 
has been started. 
 Some protocols require not commercially available citrate concentrations, and very little information is 
reported in the literature regarding the stability of diluted citrate solutions. In addition, advance 
preparation and storage in Nephrology and ICU is very important, as the prompt start of CRRT or CPFA 
procedures is critical for the treatment of patients with acute kidney failure or septic shock. 
 
What this study adds 
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 Syringes “ready-to-use” containing 50 mL of 35 mM or 90 mM sterile solutions of trisodium citrate have 
a shelf life of almost 1 month if stored at room temperature protected by light. Solutions at suitable 
concentration may be prepared by the hospital pharmacist and stored in Nephrology and ICU in order to 
be immediately available at any time. 
 The use of 90 mM trisodium citrate as regional anticoagulant during the citrate bag changes in CPFA is 
safe and more effective than heparin for the prevention of circuit clotting. 
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Legends of figures 
 
Figure 1. Chromatograms of a trisodium citrate sample (35 mM, = 215 nm) treated by forced degradation at 
oxidizing condition (a) and control (b). Arrows indicates presumed degradation products. I = injection; T = 
trisodium citrate. 
 
 
